IP Library Granted Patent US 10,390,953
Granted Patent B2
US 10,390,953 · App. 15/453,734 · Granted Aug 27, 2019

Methods and devices for reducing paravalvular leakage

Inventor: Rick Wypych (Bellevue, WA)
Assignee: Cardiac Dimensions Pty. Ltd.
A61F2/2451A61F2/2412A61F2/2466A61F2220/0008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,390,953
App. No.
15/453,734
Granted
Aug 27, 2019
Kind
B2
Abstract

Methods and devices for reducing paravalvular leakage associated with a replacement mitral valve. The methods can include monitoring for paravalvular leakage between a replacement mitral valve and tissue proximate the mitral valve annulus; if a sufficient amount of paravalvular leakage is observed, deploying a tissue reshaping device at least partially within a coronary sinus; remodeling coronary sinus tissue with the tissue reshaping device to remodel at least one of mitral valve annulus tissue, at least one mitral valve leaflet, and left atrium tissue in an attempt to reduce the paravalvular leakage; and monitoring for a reduction in paravalvular leakage after the remodeling step.

Claims (28)

1. A method of reducing paravalvular leakage associated with a replacement mitral valve, comprising:

monitoring for paravalvular leakage between a replacement mitral valve and tissue proximate the mitral valve annulus;

if paravalvular leakage is observed, deploying a tissue reshaping device solely within a coronary sinus;

intravascularly remodeling coronary sinus tissue with the tissue reshaping device deployed solely within the coronary sinus to cause the remodeling of at least one of mitral valve annulus tissue, at least one mitral valve leaflet, and left atrium tissue in an attempt to reduce the paravalvular leakage; and

monitoring for a reduction in paravalvular leakage after the remodeling step.

2. The method of claim 1 , wherein, after monitoring for a reduction in paravalvular leakage after the remodeling step, if the monitored paravalvular leakage has been reduced, maintaining the remodeling of the coronary sinus with the tissue reshaping device and maintaining the remodeling of the at least one of the mitral valve annulus tissue, mitral valve leaflets, and left atrium tissue to maintain the reduced paravalvular leakage.

3. The method of claim 2 , wherein the maintaining step comprises releasing the tissue reshaping device from a delivery device to implant the tissue reshaping device.

4. The method of claim 2 , further comprising releasing the replacement mitral valve from a delivery device.

5. The method of claim 1 , further comprising, if the monitored paravalvular leakage has been reduced, releasing the tissue reshaping device from a delivery device.

6. The method of claim 1 , further comprising, if the monitored paravalvular leakage has been reduced, releasing the replacement mitral valve from a delivery device.

7. The method of claim 6 , further comprising monitoring paravalvular leakage after releasing the replacement mitral valve from the delivery device to determine if paravalvular leakage increased as a result of releasing the replacement mitral valve from the delivery device, and if so, repeating the remodeling and second monitoring steps.

8. The method of claim 1 , further comprising, after monitoring for paravalvular leakage after the remodeling step, if the paravalvular leakage has not been reduced, further remodeling coronary sinus tissue with the tissue reshaping device to further remodel at least one of mitral valve annulus tissue, mitral valve leaflets, and left atrium tissue in an attempt to reduce paravalvular leakage, and further monitoring paravalvular leakage.

9. The method of claim 8 , further comprising, if paravalvular leakage has not been reduced, repeating the further remodeling and further monitoring steps until the paravalvular leakage has been reduced.

10. The method of claim 8 , wherein if the paravalvular leakage has been reduced, releasing the tissue reshaping device from a delivery device to thereby implant the tissue reshaping device and maintain the reduced paravalvular leakage.

11. The method of claim 8 , wherein if the paravalvular leakage has been reduced, releasing the mitral valve replacement from a delivery device.

12. The method of claim 1 , wherein remodeling coronary sinus tissue with the tissue reshaping device comprises plicating coronary sinus tissue with the tissue reshaping device.

13. The method of claim 12 , wherein deploying a tissue reshaping device comprises anchoring a first anchor of the tissue reshaping device within the coronary sinus, and wherein plicating coronary sinus tissue comprises proximally pulling on the tissue reshaping device after the first anchor is anchored within the coronary sinus.

14. The method of claim 13 , further comprising anchoring a second anchor of the tissue reshaping device against tissue when the monitored paravalvular leakage has been reduced.

15. The method of claim 13 , wherein deploying a tissue reshaping device comprises anchoring first and second anchors, and wherein plicating coronary sinus tissue comprises proximally pulling on a portion of the tissue reshaping device after the first and second anchors are anchored.

16. The method of claim 1 , wherein remodeling coronary sinus tissue with the tissue reshaping device comprises reducing the curvature of at least a portion of the coronary sinus.

17. The method of claim 1 , wherein remodeling coronary sinus tissue with the tissue reshaping device comprises increasing the curvature of at least a portion of the coronary sinus.

18. The method of claim 1 , wherein remodeling coronary sinus tissue with the tissue reshaping device is at least partially caused by pulling on the tissue reshaping device.

19. The method of claim 1 , wherein remodeling coronary sinus tissue with the tissue reshaping device is at least partially caused by straightening at least a portion of the tissue reshaping device.

20. The method of claim 1 , wherein remodeling coronary sinus tissue with the tissue reshaping device is at least partially caused by increasing the curvature of at least a portion of the tissue reshaping device.

21. The method of claim 1 , further comprising, prior to the first monitoring step, expanding the replacement mitral valve into contact with at least one of left atrial tissue, mitral valve annulus tissue, native mitral valve leaflet tissue, and left ventricular tissue.

22. The method of claim 21 , wherein the expanded replacement mitral valve remains secured to a delivery device when the remodeling step is initiated.

23. The method of claim 1 , wherein, if paravalvular leakage is observed after the first monitoring step, the method further comprises delivering the tissue reshaping device to the coronary sinus.

24. The method of claim 1 , wherein monitoring for paravalvular leakage between the replacement mitral valve and tissue proximate the mitral valve annulus comprising monitoring blood flow between the replacement mitral valve and tissue using an imaging modality.

Assignments (7)
SECURITY INTEREST Recorded Jul 16, 2025
From: CARDIAC DIMENSIONS PTY. LTD
To: FORTRESS CREDIT CORP., AS ADMINISTRATIVE AGENT
Reel/Frame 071978/0523 →
RELEASE OF SECURITY INTEREST Recorded Jul 14, 2025
From: CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.À R.L.
To: CARDIAC DIMENSIONS PTY LTD
Reel/Frame 071936/0011 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 6, 2023
From: OXFORD FINANCE LLC
To: CARDIAC DIMENSIONS PTY LTD
Reel/Frame 064224/0199 →
SECURITY INTEREST Recorded Jun 30, 2023
From: CARDIAC DIMENSIONS PTY LTD
To: CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.A R.L
Reel/Frame 064181/0642 →
FIRST AMENDMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 27, 2023
From: CARDIAC DIMENSIONS PTY LTD
To: OXFORD FINANCE LLC
Reel/Frame 063167/0447 →
SECURITY INTEREST Recorded Apr 16, 2018
From: CARDIAC DIMENSIONS PTY LTD
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 045958/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2017
From: WYPYCH, RICK
To: CARDIAC DIMENSIONS PTY. LTD.
Reel/Frame 042935/0217 →
Continuity (1)
Related Publication 20180256330A1 · Sep 13, 2018